Bayer Slips Without a Clear Trigger as Missouri Glyphosate Trial and Pipeline Wins Pull in Opposite Directions
Published on 10/01/2026 at 14:30 | Editorial boerse-global.de
Bayer shares came under pressure on two consecutive sessions this week, and the reasons behind the moves illustrate just how split the investment case has become. On Wednesday, the DAX heavyweight shed 2.7% to close at EUR 47.75, dragged down by a broadly weak market. Persistent eurozone inflation, rising oil prices and climbing bond yields pushed Germany's benchmark index firmly into the red, and Bayer offered little resistance.
The following day brought a second decline, this time of 2.3%, taking the stock to EUR 46.66. Notably, there was no obvious catalyst for Thursday's drop. Neither company-specific announcements nor fresh sector news explained the selling, which market reports said picked up noticeably during the morning hours.
A New Front in the Glyphosate Battle
What did emerge midweek was a fresh legal headache. A glyphosate trial against subsidiary Monsanto opened in the US state of Missouri on Wednesday. Three plaintiffs allege the company failed to adequately test its Roundup herbicide before bringing it to market. Crucially, the case rests on a different line of argument than the previous warning-label claims, which is why observers regard it as a bellwether test for future liability exposure.
The stakes extend beyond the courtroom itself. Should the Missouri proceedings broaden Monsanto's liability, Bayer could face further financial setbacks, and a defeat built on novel legal reasoning might seriously undermine confidence in any eventual clean-up of the legacy litigation. Institutional investors are already treading carefully. A voting rights notification filed Tuesday showed asset manager Amundi trimmed its stake, with its holding falling from 3.04% to 2.90% after crossing a threshold on 23 September. Continued withdrawals of institutional capital risk weighing on the share price even if the underlying business data hold steady.
Pharma Pipeline Delivers Regulatory Tailwinds
Against that legal backdrop, Bayer's drug development engine has been generating genuine momentum. On Monday, the FDA granted priority review to Lynkuet (Elinzanetant) for an additional indication — the treatment of moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer. Accelerated review shortens the path to potential market launch considerably.
Should investors sell immediately? Or is it worth buying Bayer?
A day later, the company's BlueRock Therapeutics unit secured orphan drug designations for its cell therapy candidate lemiretprocel (OpCT-001). The FDA awarded the status for retinitis pigmentosa and cone-rod dystrophy, while the European Medicines Agency granted it for certain inherited retinal conditions. Such designations carry meaningful advantages in pharmaceutical development, giving the sponsoring companies regulatory benefits and administrative support from the authorities during testing.
Bayer also moved to shore up its financial flexibility, placing hybrid bonds on 23 September.
Deutsche Bank Sticks With Its Call
Analyst Virginie Boucher-Ferte of Deutsche Bank Research kept her "Buy" rating and EUR 60 price target intact. Her forecast for the third quarter points to operating revenue growth of 1.3% year-on-year, paired with a 10% decline in operating earnings. The expected hit to profit stems largely from favorable one-off effects in the agricultural business that had flattered the prior-year quarter.
That projection lays bare the margin pressure still bearing down on the Leverkusen-based group's operating business, and it explains why many market participants are holding back ahead of detailed figures. The earnings power of the Crop Science division, which has been shaped heavily by swings in global commodity and crop protection markets, sits at the center of that scrutiny. The real test for investors is whether the core business is structurally profitable enough to absorb ongoing legal uncertainty and set aside reserves for potential settlements.
Chart Levels and the November Date
From a technical standpoint, the picture remains constructive as long as the stock stays above key trend lines. At EUR 47.75, the shares were still trading comfortably above their 200-day moving average of EUR 43.00. If buyers can defend that level, the medium-term uptrend stays alive; a decisive break below it would likely hand the upper hand to the bears.
The next hard catalyst is already circled on the calendar. Bayer will publish its full third-quarter results on 3 November. That interim report will show in detail how revenue and earnings actually developed — and whether operating performance can carry the day, or whether the US litigation once again seizes the narrative.
Ad
Bayer Stock: New Analysis - 1 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
